Paradigm Biocapital Advisors LP - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 122 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.4%.

Quarter-by-quarter ownership
Paradigm Biocapital Advisors LP ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$64,795,638
+157.8%
2,178,737
+56.2%
4.40%
+126.4%
Q2 2023$25,137,936
+38.1%
1,395,002
+23.0%
1.94%
+12.5%
Q1 2023$18,208,539
+11.8%
1,133,782
+27.4%
1.73%
-9.7%
Q4 2022$16,288,922
+59.7%
890,105
+71.4%
1.91%
+40.7%
Q3 2022$10,198,000519,2561.36%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q4 2022
NameSharesValueWeighting ↓
Versant Venture Management, LLC 2,030,616$31,028,0006.04%
5AM Venture Management, LLC 1,362,286$20,816,0003.75%
Burrage Capital Management LLC 272,393$4,162,0003.37%
Altium Capital Management LP 361,930$5,530,0001.54%
Vivo Capital, LLC 2,214,138$33,832,0001.19%
Bain Capital Life Sciences Investors, LLC 1,071,428$16,371,0000.93%
Perceptive Advisors 3,659,381$51,606,0000.65%
New Leaf Venture Partners, L.L.C. 141,000$2,154,0000.50%
DRIEHAUS CAPITAL MANAGEMENT LLC 2,003,688$30,616,0000.45%
Opaleye Management Inc. 188,000$2,873,0000.42%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders